

Pharmacologic properties:

Ipratropium bromide is an anticholinergic bronchodilator classified as a quaternary ammonium compound. Anticholinergics prevent the binding of acetylcholine with muscarinic receptors on bronchial smooth muscle, inhibiting bronchoconstriction. The bronchodilating effect of ipratropium is primarily local and site specific. Since it is not well absorbed systemically, there is low potential for toxicity.

Indications:

- Acute bronchospasm (wheezing) associated with asthma or COPD in adult and pediatric patients

Contraindications:

- Hypersensitivity to ipratropium, atropine or its derivatives, soy, or peanuts

Precautions:

- Use with caution in patients with narrow angle glaucoma, prostatic hypertrophy, or bladder-neck obstruction
- Contact with eyes can cause irritation and precipitation of narrow angle glaucoma

Adverse Reactions:

- Palpitations
- Nervousness
- Dizziness
- Headache
- Nausea
- GI distress
- Dry mouth
- Cough

Dosage and administration:

Adult

- 0.5 mg/2.5 ml
- Combined with Albuterol

Pediatric

- Not for use in patients under twelve years.